WEDNESDAY, April 23, 2025 — The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.The approval is for patients 12 years and older who remain…
You may also like
Some OB/GYNS Stay in States With Abortion Bans...
Teen Cannabis Use Rises in Canada After Edibles Are...
Federal Prosecutor Questions Medical Journals Over...
Psilocybin Use Dramatically Increasing In U.S.
Muscle Quality Could Be Key To Successful Hip...
Early Menopause Might Mean Greater Age-Related Brain...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.